IBRX (NASDAQ: IBRX) holder plans Rule 144 sale of 50,000 shares
Rhea-AI Filing Summary
A holder of ImmunityBio (symbol IBRX) has filed a Rule 144 notice to sell 50,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $197,500 based on the figures in the notice. The filing lists 984,965,179 shares outstanding as a baseline figure for the issuer’s common stock.
The securities to be sold were acquired on 01/16/2026 by an exercise of stock options from the issuer, paid in cash, with the same date shown for payment. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, consistent with the representations referenced in Rule 144 and any Rule 10b5-1 trading plan disclosures.
Positive
- None.
Negative
- None.
FAQ
What does the IBRX Form 144 filing disclose?
How many IBRX shares are planned to be sold under this Form 144?
What is the aggregate market value of the IBRX shares in this Form 144?
How and when were the IBRX shares in this Form 144 acquired?
Which broker and exchange are involved in this IBRX Form 144 sale?
How many IBRX shares are shown as outstanding in the Form 144?
What representation does the seller make in the IBRX Form 144?